Neurofilament-light chain (NfL) and glial fibrillary acidic protein (GFAP) are two of the main fluid biomarkers currently being examined for their clinical utility in evaluating disease activity, progression and treatment response. However, there are a number of other biomarkers under investigation. The following is a summary of some of the more promising candidates (reviewed in Maroto-Garcia et al. Clin Chim Acta 2023;548:117471). Read More
Latest News
sNfL a useful alternative to gadolinium
July 31, 2023The prospective REDUCE-GAD study reports that higher serum neurofilament-light chain (NfL) levels are associated with the presence of contrast-enhancing (CE) lesions, which may enable clinicians to forego contrast agents for follow-up MRIs (Schaefer et al. Eur J Neurol 2023;30:2393-2400). Read More
CLINICAL CASES IN MS – A DIAGNOSTIC DILEMMA
July 26, 2023Click here to watch Dr. Daniel Selchen discuss the case and the responses to the survey.
Ken, a 53-year-old man, was initially seen in 2017 following onset of painful spasms in R leg and probable clonus while driving his car. He developed R leg weakness and band-like discomfort across his chest. He was worked up for stroke and cardiac issues and all investigations were negative. He had a prior history of asthma with nasal polyps and NSAID-associated dyspnea.
Revised recommendations on the differential diagnosis of MS
July 25, 2023The Multiple Sclerosis Differential Diagnosis Consortium has published consensus recommendations on the differential diagnosis of multiple sclerosis (Solomon et al. Lancet Neurol 2023;22:750-768). This version updates recommendations published 15 years ago (Miller et al. Mult Scler 2008;14:1157-1174). Read More